The real-world safety profile of enfortumab vedotin with or without pembrolizumab: insights from a comparative analysis of FAERS
IntroductionThe combination of enfortumab vedotin and pembrolizumab (EV+P) has revolutionized advanced urothelial carcinoma treatment, yet their combined real-world safety profile remains insufficiently characterized. This study aimed to quantitatively compare the adverse event (AE) landscapes of EV...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2026-07-01
|
| Col·lecció: | Frontiers in Immunology |
| Matèries: | |
| Accés en línia: | https://www.frontiersin.org/articles/10.3389/fimmu.2026.1831172/full |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|